Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives $32.73 Average PT from Analysts

Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seven brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $32.73.

A number of brokerages have recently weighed in on OTLK. BTIG Research lowered their price target on Outlook Therapeutics from $50.00 to $9.00 and set a "buy" rating for the company in a report on Friday, November 29th. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price objective on shares of Outlook Therapeutics in a report on Friday, November 29th. Finally, Chardan Capital reissued a "neutral" rating on shares of Outlook Therapeutics in a research note on Monday, December 2nd.

Institutional Investors Weigh In On Outlook Therapeutics

A number of large investors have recently bought and sold shares of the business. Great Point Partners LLC increased its holdings in shares of Outlook Therapeutics by 15.0% during the 2nd quarter. Great Point Partners LLC now owns 1,701,510 shares of the company's stock valued at $12,557,000 after acquiring an additional 221,510 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Outlook Therapeutics by 49.2% in the third quarter. Geode Capital Management LLC now owns 341,959 shares of the company's stock valued at $1,826,000 after purchasing an additional 112,812 shares during the period. State Street Corp lifted its stake in shares of Outlook Therapeutics by 10.0% in the third quarter. State Street Corp now owns 232,542 shares of the company's stock worth $1,242,000 after buying an additional 21,201 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Outlook Therapeutics by 55.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 51,459 shares of the company's stock worth $275,000 after buying an additional 18,287 shares during the period. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Outlook Therapeutics during the 2nd quarter worth $303,000. 11.20% of the stock is currently owned by institutional investors.

Outlook Therapeutics Stock Down 3.4 %

Shares of Outlook Therapeutics stock traded down $0.08 during trading hours on Monday, hitting $2.29. The company's stock had a trading volume of 572,626 shares, compared to its average volume of 1,170,601. The company has a market capitalization of $57.03 million, a PE ratio of -0.21 and a beta of 0.53. The business has a fifty day moving average of $3.11 and a 200 day moving average of $5.51. Outlook Therapeutics has a 1-year low of $0.87 and a 1-year high of $12.85.

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last released its quarterly earnings data on Friday, December 27th. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.06. On average, sell-side analysts anticipate that Outlook Therapeutics will post -3.84 earnings per share for the current fiscal year.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.